
Lupin completes acquisition of US-based Gavis Pharmaceuticals
pharmafile | March 10, 2016 | News story | Research and Development, Sales and Marketing | FDA, Gavis, Lupin, acquisition, generics
Indian drug manufacturer Lupin has announced the completion of its acquisition of New Jersey-based pharmaceutical firm, Gavis, in a deal worth $880 million.
As reported previously, the deal will see Lupin enhance its presence in the US generic market, with access to Gavis’ 62 generic drugs, which the firm has already filed to the FDA for approval.
72% of these ANDA filings pending approval requests represent niche dosage forms with 18 Para IVs and eight FTFs products. The existing pending approvals of Gavis address a market of over $9 billion.
Vinita Gupta, chief executive officer at Lupin, comments: “We are very pleased to have completed our acquisition of Gavis. The Gavis portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin’s generic as well as speciality pipeline.”
Sean Murray
Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …





